🇪🇺 Xydalba in European Union

EMA authorised Xydalba on 19 February 2015

Marketing authorisation

EMA — authorised 19 February 2015

  • Application: EMEA/H/C/002840
  • Marketing authorisation holder: AbbVie Deutschland GmbH & Co. KG
  • Local brand name: Xydalba
  • Indication: Xydalba is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients from birth (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents.
  • Status: approved

Read official source →

Other Infectious Disease approved in European Union

Frequently asked questions

Is Xydalba approved in European Union?

Yes. EMA authorised it on 19 February 2015.

Who is the marketing authorisation holder for Xydalba in European Union?

AbbVie Deutschland GmbH & Co. KG holds the EU marketing authorisation.